

#### 11 November 2019

Australian Securities Exchange 20 Bridge Street, Sydney NSW 2000

## Notice under section 708A(5)(e) of the Corporations Act

**Melbourne, Victoria** - This notice is given by Alcidion Group Limited (ASX:ALC) (Alcidion) under section 708A(5)(e) of the Corporations Act 2001 (Cth) (Corporations Act).

The Company hereby confirms that:

- a) it has issued 90,000,000 fully paid ordinary shares (**Shares**) to professional and sophisticated investors at an issue price of \$0.18 (18 cents) per Share.
- b) the New Shares were issued without disclosure to investors under Part 6D.2 of the Corporations Act;
- c) it is providing this notice under paragraph 5(e) of section 708A of the Corporations Act;
- d) as at the date of this notice the Company, as a disclosing entity under the Corporations Act, has complied with:
  - (i) the provisions of Chapter 2M of the Corporations Act as they apply to Alcidion; and
  - (ii) section 674 of the Corporations Act; and
- e) as at the date of this notice, there is no excluded information of the type referred to in subsections 708A(7) and 708A(8) of the Corporations Act.

#### Additional Disclosures under ASX LR3.10.5A

The Company provides the below additional disclosure in relation to ASX Listing Rule 7.1A4(b) and 3.10.5A following the issue of 90,000,000 fully paid ordinary shares on this day.

a) Details of the dilution to existing holders of ordinary securities caused by the issue:

	Number	Dilution
Shares on issue prior to placement	900,694,052	
Shares to be issued under LR7.1 placement capacity	10,000,000	1.11%
Shares to be issued under LR7.1A placement capacity	80,000,000	8.88%
Total Shares on issue after completion of the Placement	990,694,052	



- b) The Company issued the relevant shares in accordance with ASX Listing Rule 7.1A in order for the Company to raise the funds required to carry out its objectives. The Company believes that the Issue:
  - was the most cost-efficient and expedient method available to it at the time;
  - provided funding certainty; and
  - matched sophisticated investor enquiry.
- c) There were no underwriting arrangements for the Issue.
- d) There were fees of 6% incurred in connection with the issue under ASX Listing Rule 7.1A.

An Appendix 3B relating to the issue of shares noted above is attached.

#### ENDS

For further information, please contact:

Kyahn Williamson, WE Buchan Ph: 0401018828 kwilliamson@we-buchan.com

#### About Alcidion

Alcidion Limited (ASX:ALC) has a simple purpose: to transform healthcare with smart, intuitive technology solutions that meet the needs of hospital and allied healthcare, worldwide. It offers a complementary set of software products and services that create a unique offering in the global healthcare market; solutions that support interoperability, allow communication and task management, and deliver clinical decision support at the point of care to improve patient outcomes. In 2017 Alcidion acquired Oncall System and its Smartpage clinical communication system. In 2018 it acquired the Patientrack bedside patient monitoring software and MKM Health, an IT solutions and services provider. These offerings now operate under the Alcidion brand. With over 25 years of combined healthcare experience, Alcidion brings together the very best in technology and market knowledge to deliver solutions that make healthcare better for everyone.

#### www.alcidion.com

© Alcidion Group Limited 2019. Alcidion, MKM Health, Miya, Patientrack and Smartpage are registered trademarks. All other brands and product names and trademarks are the registered property of their respective companies.

Level 10/9 Yarra Street South Yarra VIC 3141 Australia

Rule 2.7, 3.10.3, 3.10.4, 3.10.5

# Appendix 3B

## New issue announcement, application for quotation of additional securities and agreement

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 01/07/96 Origin: Appendix 5 Amended 01/07/98, 01/09/99, 01/07/00, 30/09/01, 11/03/02, 01/01/03, 24/10/05, 01/08/12, 04/03/13

Name of entity

ALCIDION GROUP LIMITED

ABN

77 143 142 410

We (the entity) give ASX the following information.

#### Part 1 - All issues

You must complete the relevant sections (attach sheets if there is not enough space).

1 +Class of +securities issued or to be issued

Fully paid ordinary shares

- 2 Number of \*securities issued or to be issued (if known) or maximum number which may be issued
- 3 Principal terms of the \*securities (e.g. if options, exercise price and expiry date; if partly paid \*securities, the amount outstanding and due dates for payment; if \*convertible securities, the conversion price and dates for conversion)

Fully paid ordinary shares	

<sup>+</sup> See chapter 19 for defined terms.

4	<ul> <li>Do the *securities rank equally in all respects from the *issue date with an existing *class of quoted *securities?</li> <li>If the additional *securities do not rank equally, please state: <ul> <li>the date from which they do</li> <li>the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment</li> <li>the extent to which they do not rank equally, other than in relation to the next</li> </ul> </li> </ul>	Yes, the shares issued will rank equally with existing ordinary shares on issue
	dividend, distribution or interest payment	
5	Issue price or consideration	\$0.18 (18 cents)
6	Purpose of the issue (If issued as consideration for the acquisition of assets, clearly identify those assets)	Fully paid ordinary shares issued to professional and sophisticated investors. The proceeds raised will be used to fund accelerated revenue growth and support scale of the business.
6a	Is the entity an <sup>+</sup> eligible entity that has obtained security holder approval under rule 7.1A?	Yes
	If Yes, complete sections 6b – 6h <i>in relation to the</i> + <i>securities</i> <i>the subject of this Appendix 3B</i> , and comply with section 6i	
6b	The date the security holder resolution under rule 7.1A was passed	25 October 2018
6c	Number of <sup>+</sup> securities issued without security holder approval under rule 7.1	10,000,000 Fully paid ordinary shares
6d	Number of <sup>+</sup> securities issued with security holder approval under rule 7.1A	80,000,000 Fully paid ordinary shares

<sup>+</sup> See chapter 19 for defined terms.

- 6e Number of \*securities issued Nil with security holder approval under rule 7.3, or another specific security holder approval (specify date of meeting)
- 6f Number of +securities issued under an exception in rule 7.2
- 6g If +securities issued under rule 7.1A, was issue price at least 75% of 15 day VWAP as calculated under rule 7.1A.3? Include the +issue date and both values. Include the source of the VWAP calculation.
- 6h If +securities were issued under rule 7.1A for non-cash consideration, state date on which valuation of consideration was released to ASX Market Announcements
- 6i Calculate the entity's remaining issue capacity under rule 7.1 and rule 7.1A – complete Annexure 1 and release to ASX Market Announcements
- 7 +Issue dates

Note: The issue date may be prescribed by ASX (refer to the definition of issue date in rule 19.12). For example, the issue date for a pro rata entitlement issue must comply with the applicable timetable in Appendix 7A.

Cross reference: item 33 of Appendix 3B.

8 Number and \*class of all \*securities quoted on ASX (*including* the \*securities in section 2 if applicable)

Number	+Class
990,694,052	Fully paid ordinary shares

Nil

The 15 day VWAP as calculated in accordance with ASX LR 7.1A.3 and issue price of at least 75% was \$0.17 (17 cents) per share. The price was set on 1 November 2019 and the shares have been issued on 11 November 2019. The calculation of the 15 day VWAP was carried out by the Company.

N/A

Refer Annexure 1

11 November 2019

<sup>+</sup> See chapter 19 for defined terms.

- 9 Number and \*class of all \*securities not quoted on ASX (*including* the \*securities in section 2 if applicable)
- 10 Dividend policy (in the case of a trust, distribution policy) on the increased capital (interests)

+Class	
	+Class

Part 2 - Pro rata issue

SECTION NOT APPLICABLE

## Part 3 - Quotation of securities

You need only complete this section if you are applying for quotation of securities

- 34 Type of +securities (*tick one*)
- (a) +Securities described in Part 1
- (b) All other +securities

Example: restricted securities at the end of the escrowed period, partly paid securities that become fully paid, employee incentive share securities when restriction ends, securities issued on expiry or conversion of convertible securities

### Entities that have ticked box 34(a)

#### Additional securities forming a new class of securities

Tick to indicate you are providing the information or documents

35 If the \*securities are \*equity securities, the names of the 20 largest holders of the additional \*securities, and the number and percentage of additional \*securities held by those holders

If the \*securities are \*equity securities, a distribution schedule of the additional \*securities setting out the number of holders in the categories

 1,000
 0,001 - 5,000
 0,001 - 10,000
 100,001 and over

A copy of any trust deed for the additional +securities

37

<sup>+</sup> See chapter 19 for defined terms.

## Entities that have ticked box 34(b)

38	Number of *securities for which *quotation is sought	Nil	
39	*Class of *securities for which quotation is sought	N/A	
40	Do the *securities rank equally in all respects from the *issue date with an existing *class of quoted *securities?	N/A	
	<ul> <li>If the additional *securities do not rank equally, please state:</li> <li>the date from which they do</li> <li>the extent to which they garticipate for the next dividend, (in the case of a trust, distribution) or interest payment</li> <li>the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment</li> </ul>		
41	Reason for request for quotation now Example: In the case of restricted securities, end of restriction period (if issued upon conversion of another *security, clearly identify that other *security)	N/A	
42	Number and <sup>+</sup> class of all <sup>+</sup> securities quoted on ASX ( <i>including</i> the <sup>+</sup> securities in clause 38)	Number	+Class

<sup>+</sup> See chapter 19 for defined terms.

#### Quotation agreement

- <sup>1</sup> <sup>+</sup>Quotation of our additional <sup>+</sup>securities is in ASX's absolute discretion. ASX may quote the <sup>+</sup>securities on any conditions it decides.
- 2 We warrant the following to ASX.
  - The issue of the \*securities to be quoted complies with the law and is not for an illegal purpose.
  - There is no reason why those +securities should not be granted +quotation.
  - An offer of the \*securities for sale within 12 months after their issue will not require disclosure under section 707(3) or section 1012C(6) of the Corporations Act.

Note: An entity may need to obtain appropriate warranties from subscribers for the securities in order to be able to give this warranty

- Section 724 or section 1016E of the Corporations Act does not apply to any applications received by us in relation to any \*securities to be quoted and that no-one has any right to return any \*securities to be quoted under sections 737, 738 or 1016F of the Corporations Act at the time that we request that the \*securities be quoted.
- If we are a trust, we warrant that no person has the right to return the \*securities to be quoted under section 1019B of the Corporations Act at the time that we request that the \*securities be quoted.
- 3 We will indemnify ASX to the fullest extent permitted by law in respect of any claim, action or expense arising from or connected with any breach of the warranties in this agreement.
- We give ASX the information and documents required by this form. If any information or document is not available now, we will give it to ASX before +quotation of the +securities begins. We acknowledge that ASX is relying on the information and documents. We warrant that they are (will be) true and complete.

MELANIE LEYDIN Company Secretary

11 November 2019

<sup>+</sup> See chapter 19 for defined terms.

## Appendix 3B – Annexure 1

# Calculation of placement capacity under rule 7.1 and rule 7.1A for eligible entities

Introduced 01/08/12 Amended 04/03/13

## Part 1

Rule 7.1 – Issues exceeding 15% of capital		
Step 1: Calculate "A", the base figure from which the placement capacity is calculated		
805,671,138		
5,000,000 – 16 July 2019 5,000,000 – 27 August 2019 -		
815,671,138		

<sup>+</sup> See chapter 19 for defined terms.

Step 2: Calculate 15% of "A"	
"B"	0.15 [Note: this value cannot be changed]
<i>Multiply</i> "A" by 0.15	122,350,670
Step 3: Calculate "C", the amount of that has already been used	placement capacity under rule 7.1
<ul> <li>Insert number of *equity securities issued or agreed to be issued in that 12 month period not counting those issued:</li> <li>Under an exception in rule 7.2</li> <li>Under rule 7.1A</li> <li>With security holder approval under rule 7.1 or rule 7.4</li> <li>Note:</li> <li>This applies to equity securities, unless specifically excluded – not just ordinary securities</li> <li>Include here (if applicable) the securities the subject of the Appendix 3B to which this form is annexed</li> <li>It may be useful to set out issues of securities on different dates as separate line items</li> </ul>	79,156,471 - 4 October 2019 5,866,443 - 4 October 2019 10,000,000 – 11 November 2019
"C"	95,022,914
Step 4: Subtract "C" from ["A" x "B" capacity under rule 7.1 "A" x 0.15 Note: number must be same as shown in Step 2	<i>to calculate remaining placement</i>
Subtract "C" Note: number must be same as shown in Step 3	(95,022,914)
<i>Total</i> ["A" x 0.15] – "C"	<b>27,327,756</b> Note: this is the remaining placement capacity under rule 7.1

<sup>+</sup> See chapter 19 for defined terms.

## Part 2

Rule 7.1A – Additional placem	ent capacity for eligible entities	
Step 1: Calculate "A", the base figure from which the placement capacity is calculated		
"A"	815,671,138	
Note: number must be same as shown in Step 1 of Part 1		
Step 2: Calculate 10% of "A"		
"D"	0.10	
	Note: this value cannot be changed	
<i>Multiply</i> "A" by 0.10	81,567,113	
Step 3: Calculate "E", the amount of that has already been used	placement capacity under rule 7.1A	
<b>Insert</b> number of *equity securities issued or agreed to be issued in that 12 month period under rule 7.1A	80,000,000 – 11 November 2019	
<ul> <li>Notes:</li> <li>This applies to equity securities – not just</li> </ul>		
ordinary securities		
• Include here – if applicable – the securities the subject of the Appendix 3B to which		
<ul><li>this form is annexed</li><li>Do not include equity securities issued</li></ul>		
under rule 7.1 (they must be dealt with in		
Part 1), or for which specific security holder approval has been obtained		
<ul> <li>It may be useful to set out issues of securities on different dates as separate</li> </ul>		
line items		
"E"	80,000,000	
Step 4: Subtract "E" from ["A" x "D"] capacity under rule 7.1A	to calculate remaining placement	
"A" x 0.10	81,567,113	
Note: number must be same as shown in Step 2		
Subtract "E"	(80,000,000)	
Note: number must be same as shown in Step 3		
<i>Total</i> ["A" × 0.10] – "E"	1,567,113	
	Note: this is the remaining placement capacity under rule 7.1A	

<sup>+</sup> See chapter 19 for defined terms.